RT Journal Article
SR Electronic
T1 A second update on mapping the human genetic architecture of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.24.22283874
DO 10.1101/2022.12.24.22283874
A1 ,
A1 Ganna, Andrea
YR 2022
UL http://medrxiv.org/content/early/2022/12/27/2022.12.24.22283874.abstract
AB Investigating the role of host genetic factors in COVID-19 severity and susceptibility can inform our understanding of the underlying biological mechanisms that influence adverse outcomes and drug development1,2. Here we present a second updated genome-wide association study (GWAS) on COVID-19 severity and infection susceptibility to SARS-CoV-2 from the COVID-19 Host Genetic Initiative (data release 7). We performed a meta-analysis of up to 219,692 cases and over 3 million controls, identifying 51 distinct genome-wide significant loci—adding 28 loci from the previous data release2. The increased number of candidate genes at the identified loci helped to map three major biological pathways involved in susceptibility and severity: viral entry, airway defense in mucus, and type I interferon.Competing Interest StatementA full list of competing interests is available in Supplementary Table 11.Funding StatementA full list of acknowledgement is available in Supplementary Table 11.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical statements for each contributing study are given in Supplementary Table 1.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics generated by COVID-19 HGI are available online, including per-ancestry summary statistics for African, Admixed American, East Asian, European, and South Asian ancestries　(https://www.covid19hg.org/results/r7/). The analyses described here utilize the data release 7. If available, individual-level data can be requested directly from contributing studies, listed in Supplementary Table 1. We used publicly available data from GTEx (https://gtexportal.org/home/), the Neale lab (http://www.nealelab.is/uk-biobank/), Finucane lab (https://www.finucanelab.org), FinnGen Freeze 4 cohort (https://www.finngen.fi/en/access_results), and eQTL catalogue release 3 (http://www.ebi.ac.uk/eqtl/). https://www.covid19hg.org/results/r7/